Cellevate AB, a Lund, Sweden-based biotechnology company, announced the appointment of Christel Fenge, Ph.D., as chief technology officer (CTO) and member of the management team.
Fenge has served as a strategic advisor to Cellevate since June 2024 and brings more than 30 years of experience in leadership roles within the bioprocessing and biopharmaceutical industries. Previous positions include vice president of bioprocess research and development at Cytiva, and vice president of marketing and product management at Sartorius.
“I am delighted to take on the role of CTO at Cellevate,” Fenge says. “The company’s commercially available nanofiber-based cell culture systems have already shown great potential in biomanufacturing and I look forward to supporting the team as we now have moved into commercialization and scale-up.”
“Bringing Fenge into the management team strengthens our ability to accelerate the commercialization and the strategic partnerships with customers and turnkey solution providers in bioprocessing,” says Laura Chirica, CEO of Cellevate. “Her deep expertise in upstream bioprocessing, combined with strategic leadership, will be invaluable as we continue to commercialize and implement Cellevat3d® nanofiber cell culture solutions in new therapeutic large-scale applications, develop new product families and position our company as a proven provider in this industry.”
Leave A Comment